NCT02452502View on ClinicalTrials.gov

The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke

NACompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

September 2, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

August 31, 2018

Conditions
Stroke
Interventions
DEVICE

atorvastatin

Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months

Trial Locations (2)

310009

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

Unknown

Jilin First Hospital, Changchun

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT02452502 - The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter